This study characterises the somatostatin binding site in human gastrointestinal cancer and mucosa in terms of cationic specificity and relative affinity for three somatostatin analogues. Competitive displacement assays were performed on plasma membranes from human gastric and colonic tissues using radiolabelied somatostatin-14 as ligand. Comparison was made with the somatostatin binding site in rat cerebral cortex. In gastrointestinal tissue, magnesium decreased and sodium increased specific binding. By contrast, in rat cerebral cortex, the converse cationic effect was seen. These changes resulted from alterations in receptor density, with no change in receptor affinity. Displacement studies were then performed with somatostatin-14 and somatostatin analogues RC-160, somatuline, and octreotide. RC-160 and somatuline displaced radiolabel from binding sites in gastric and colonic cancer and mucosa with 10-fold lower affinity than the native peptide. Octreotide did not displace radioligand in gastric or colonic cancer at any concentration tested. By contrast, in rat cortex, although all three analogues displaced with a lower affinity than the native peptide, there was no difference between analogues. These data suggest a distinct somatostatin receptor subtype in gastrointestinal tissues.
Somatostatin is a potent inhibitory peptide that exists naturally in at least two forms. Originally described' was the 'somatotropin release inhibitory factor' (SRIF), which is now known as somatostatin-14. Within the central nervous system somatostatin-14 and somatostatin-28 act as neurotransmitters and are influential in the regulation of sleep, motor activity, and limbic system activity.2 Outside of this system, somatostatin has a number of regulatory activities. In the gastrointestinal tract it inhibits endocrine and exocrine secretion, decreases smooth muscle contractility and reduces mesenteric blood flow and absorption of water, amino acids, and triglycerides.3 A further effect is as a natural antiproliferative agent and recent studies have suggested that longacting somatostatin analogues may be of value in the treatment of a variety of malignancies. 4 It 10 ,uM somatostatin-14 (Sigma Ltd, UK). Displacement curves were constructed using somatostatin-14 as competitor over the concentration range 10 "M to 10-5M. After a one hour incubation at 300C, the reaction was stopped by the addition of0 5 ml ice cold saline, and the bound fraction collected by centrifugation at 13 000 g for two minutes in a Microcentaur microcentrifuge (MSE Ltd, UK). The supernatant was removed by suction and the pellet washed once with 0 5 ml ice cold saline. The pellet was counted in the reaction tube on a Packard Cobra II Autogammacounter (Canberra Packard, Pangbourne, Berks, UK). All assay points were performed in triplicate and the coefficient of variation of each triplicate was <10%.
DISPLACEMENT Table I shows these data, which are consistent with previous reports.621
Displaceable binding occurred in nine of 11 gastric and eight of 10 colonic samples (approximately 70-80% of samples examined). Sufficient material was available in six ofnine gastric and six ofeight colonic binding site positive cases for further studies to be performed. Somatostatin binding in both gastric and colonic tissues ('normal' and malignant) was seen to be of low affinity and high capacity (Table I) . Binding affinity in gastric adenocarcinoma was about two to threefold higher than in gastric mucosa, although there was no difference in binding affinity when comparing colonic mucosa and tumour. The receptor density was higher in gastric mucosa, but the other tissues differed little.
CATIONIC INFLUENCE ON SOMATOSTATIN BINDING
Over the concentration range 80-160 mM Na+, there was a significant (p<001) reduction in specific binding to rat cerebral cortex membranes to 48% of that seen in the absence of cations. By contrast with rat cerebral cortex, the addition of Na+ to membrane preparations from gastrointestinal tissues increased the specific binding to 130-165% of that seen in the absence of cations (p<0-001). This increase was seen over the concentration range 60-160 mM. Figure 1 shows these data.
In rat cerebral cortex, addition of magnesium resulted in a modest increase in specific binding reaching 135% of that in the absence of cations at a concentration of 3 (Fig 2) . In rat cerebral cortex all three analogues studied native somatostatin-14 (C), somatuline (A), RC-160 (°), displaced radiolabel in competitive assays (Fig 3) and octreotide (0) in rat cerebral cortex. Values are mean (SEM) percentage specific bindingfrom six tissue samples (in although the displacement curves were shifted triplicate) at each concentration tested. considerably to the right. Somatuline and RC-160 displaced with comparable IC,, values (about 400-fold lower affinity than native somatostatin), while octreotide displaced with about 2000-fold lower affinity than the native peptide (Table II) . Table II shows somatuline and RC-160 displaced radiolabel with IC,0 values in gastric carcinoma. Maximal displacement occurred at 10-'M for both peptides with mean (SEM) displacement of 76-7% (9-1) and 79-8% (7-5) respectively of specific binding (compared with a maximal 100% displacement with somatostatin-14). Octreotide (10-'M) maximally displaced only 47-3% (10-3) of specific binding, however, there being insufficient displacement to calculate an IC,,. Fig 4A gives the mean displacement data expressed graphically. In gastric mucosa, somatuline and RC-160 displaced with similar IC,,, values to those in gastric adenocarcinoma (see Table II ). Maximal reduction (10-'M) of specific binding was appreciably lower, however, than that occurring in gastric adenocarcinoma (59-2% (4-3) and 47% (6-7) respectively). Octreotide did not significandy displace ['25I]-tyr-l 1-somatostatin-14 from any of the samples tested and indeed mean maximal displacement at 10-'M of only 14-2% (6-3) was seen.
The findings in colonic adenocarcinoma for somatuline and RC-160 were remarkably similar to those seen in gastric adenocarcinoma (IC,,, values shown in Table II ). Maximal reduction in specific binding occurred at 10-5M with 87-5% (6-7) and 95-5% (3-2) displacement of radiolabel compared with the native peptide. Again, octreotide produced insufficient displacement to calculate an IC,,,, with only 45-4% (8-2) mean maximal displacement at 10-'M analogue concentration. Fig 4B gives the displacement data expressed graphically.
In colonic mucosa, somatuline and RC-160 displaced radiolabel to a greater degree than in gastric mucosa (maximal 74-8% and 85-8% (5-4) displacement at 10-5M). Octreotide (10-'M) displaced 45-3% (9-2) of specific binding, again preventing the calculation of an IC,,,.
Discussion
The identification of somatostatin receptor subtypes in gastrointestinal tissues and their full characterisation, especially in terms of the binding affinities of stable analogues, is important in assessing the potential of these agents in the treatment of gastrointestinal malignancy. This is particularly the case if the anti-proliferative effect of somatostatin is a direct one. Analogues that have potent anti-secretory effects on endocrine cells by specific receptor subtypes may not be particularly active as anti-proliferative agents in tissues that predominantly express a different binding site. The potential for endocrine treatment of advanced gastrointestinal malignancy is, however, enormous. These malignancies have a poor prognosis and respond only incompletely to intensive chemotherapy. They are common and, hence, even a modest benefit in terms of survival, similar to that found with endocrine manipulations in breast cancer,22 would be an important advance.
This study confirms previous reports showing that high affinity somatostatin binding is present in rat cerebral cortex, and that this binding is increased by magnesium and reduced by sodium.'3 Binding data now suggest that these changes are brought about through a change in receptor density with no significant change in receptor affinity. In human gastrointestinal tissues, a different pattern of somatostatin binding is seen. At these low affinity, high capacity binding sites the converse cationic effect seems to apply: specific binding is increased in the presence of sodium and reduced by magnesium. Further, the increased specific binding noted in the presence of sodium is reduced when magnesium is added to the system. In common with the situation in rat cerebral cortex, there is no significant change in the receptor affinity, the increased binding being brought about by increased receptor density. Taken together these data suggest that the low affinity binding seen in gastrointestinal tissues entails a different receptor subtype from the high affinity binding site in rat cerebral cortex. In terms of the effects of cations the binding site has some similarities to the 'somatostatin receptor type-2' site of Reubi, 8 except that the affinity is much lower.
All somatostatin analogues tested competed at the high affinity somatostatin binding site in rat cerebral cortex, albeit with a lower affinity than the native peptide. Similarly in gastrointestinal tissues, we saw a 'right shift' in the displacement curves with somatostatin analogues as competitor compared with the native peptide. There was also an appreciable difference in the binding affinities of the three analogues, with RC-160 and somatuline having similar potencies but octreotide displacing the native peptide only in very few tumours, and then only at very high concentrations. This is despite the fact that the anti-secretory effects of the three analogues are very similar. 
